PXVX-0200

US firm PaxVax scores USD22 million in Series B for late-stage cholera vaccine

California-based pharmaceutical company PaxVax Inc raised USD22 million in a Series B funding round for the late-stage trial of its single-dose oral cholera vaccine for travelers.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics